StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Constant Currency Growth in Rest of World (% cc) by Quarter

Constant Currency Growth in Rest of World (% cc) (%)

Novartis Constant Currency Growth in Rest of World (% cc): -61.0% in Q3 2026, down 62.0 pts from a year earlier. That is the lowest of the 32 quarters on record here.

Latest, Q3 2026
-61.0%
Period ended Sep 30, 2026
Change on a year earlier
-62.0 pts
1.0% in Q3 2025
History
32 quarters
Since Q4 2018
Sources
32
Documents cited below

Where the Q3 2026 figure comes from

“|| Promacta/Revolade | Established brands | Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) | 34 | – 61 | 108 | – 61 | – 61 | 142 | – 61 | – 61”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedConstant Currency Growth in Rest of World (% cc) (%)Year on yearSource
Q3 2026Sep 30, 2026-61.0%-62.0 ptsNovartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026-50.0%-53.0 ptsNovartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026-42.0%-49.0 ptsNovartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025-28.0%-30.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 20251.0%-2.0 ptsNovartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 20253.0%+2.0 ptsNovartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 20257.0%+11.0 ptsNovartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 20242.0%+1.0 ptsNovartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 20243.0%-5.0 ptsNovartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 20241.0%-4.0 ptsNovartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 2024-4.0%-22.0 ptsNovartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 20231.0%-6.0 ptsNovartis Form 6-K (0001370368-24-000007) ↗
Q3 2023Sep 30, 20238.0%+8.0 ptsNovartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 20235.0%-1.0 ptsNovartis Form 6-K (0001370368-23-000059) ↗
Q1 2023Mar 31, 202318.0%+11.0 ptsNovartis Form 6-K (0001370368-23-000046) ↗
Q4 2022Dec 31, 20227.0%-7.0 ptsNovartis Form 6-K (0001370368-23-000008) ↗

Cite this data

StockData. (2026). Novartis Constant Currency Growth in Rest of World (% cc) (%), quarterly Q4 2018–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-promacta-revolade-row-yoy-cc-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.